Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
Palantir
PLTR
5
Advanced Micro Devices
AMD
(FY)Dec 31, 2024 | (Q9)Sep 30, 2024 | (Q6)Jun 30, 2024 | (Q3)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q9)Sep 30, 2023 | (Q6)Jun 30, 2023 | (Q3)Mar 31, 2023 | (FY)Dec 31, 2022 | (Q9)Sep 30, 2022 | |
---|---|---|---|---|---|---|---|---|---|---|
Turnover | 7.18%7.26B | 2.69%5.48B | 2.63%4.05B | 7.73%2.22B | 13.04%6.77B | 28.91%5.34B | 30.91%3.95B | 42.04%2.06B | 10.95%5.99B | 5.24%4.14B |
Operating income | 7.18%7.26B | 2.63%4.05B | 13.04%6.77B | 30.91%3.95B | 10.95%5.99B | |||||
Cost of sales | -11.62%-4.38B | ---- | -5.61%-2.51B | ---- | -15.47%-3.93B | ---- | -38.22%-2.38B | ---- | -9.35%-3.4B | ---- |
Operating expenses | -11.62%-4.38B | -8.07%-3.31B | -5.61%-2.51B | -18.84%-1.37B | -15.47%-3.93B | -31.08%-3.06B | -38.22%-2.38B | -52.70%-1.15B | -9.35%-3.4B | -13.65%-2.33B |
Gross profit | 1.05%2.88B | -1.90%1.54B | 9.87%2.85B | 21.17%1.57B | 13.12%2.59B | |||||
Selling expenses | -21.02%-1.31B | ---- | -7.43%-664.3M | ---- | -19.06%-1.08B | ---- | -24.56%-618.36M | ---- | -22.85%-907.57M | ---- |
Administrative expenses | 8.56%-579.62M | ---- | 23.70%-239.06M | ---- | -31.16%-633.88M | ---- | -38.42%-313.31M | ---- | -1.15%-483.29M | ---- |
Impairment and provision | 68.02%-5.47M | ---- | -133.53%-1.73M | ---- | -233.42%-17.09M | ---- | 153.59%5.16M | ---- | 177.21%12.81M | ---- |
-Other impairment is provision | 68.02%-5.47M | ---- | -133.53%-1.73M | ---- | -233.42%-17.09M | ---- | 153.59%5.16M | ---- | 177.21%12.81M | ---- |
Special items of operating profit | 166.67%432K | ---- | -93.33%12K | ---- | 124.62%162K | ---- | 128.57%180K | ---- | -541.61%-658K | ---- |
Operating profit | -11.74%985.16M | -1.34%632.05M | -7.99%1.12B | 14.37%640.63M | 12.38%1.21B | |||||
Financing income | -19.38%76.87M | ---- | 4.18%44.27M | ---- | 83.86%95.35M | ---- | 124.41%42.5M | ---- | 77.16%51.86M | ---- |
Financing cost | -38.53%-68.3M | ---- | -31.17%-32.67M | ---- | 8.36%-49.3M | ---- | 11.87%-24.91M | ---- | 12.94%-53.8M | ---- |
Special items of earning before tax | 34,859.07%67.47M | ---- | 2,513.21%46.88M | ---- | -76.20%193K | ---- | 979.41%1.79M | ---- | 142.00%811K | ---- |
Earning before tax | -8.71%1.06B | 4.62%690.53M | -4.09%1.16B | 19.87%660.01M | 15.97%1.21B | |||||
Tax | -2.43%-174.28M | ---- | -7.73%-107.75M | ---- | 19.12%-170.14M | ---- | -1.65%-100.02M | ---- | -18.05%-210.37M | ---- |
After-tax profit from continuing operations | -10.62%886.93M | 4.07%582.78M | -0.93%992.31M | 23.84%560M | 15.55%1B | |||||
Earning after tax | -10.62%886.93M | 4.07%582.78M | -0.93%992.31M | 23.84%560M | 15.55%1B | |||||
Minority profit | -9.20%365.14M | ---- | -19.71%154.03M | ---- | -3.97%402.13M | ---- | 43.29%191.85M | ---- | 16.45%418.73M | ---- |
Profit attributable to shareholders | -11.59%521.8M | 6.26%546.41M | 16.46%428.75M | 12.98%237.7M | 1.25%590.19M | 36.09%514.2M | 15.65%368.15M | 30.38%210.39M | 14.91%582.89M | -2.08%377.84M |
Basic earnings per share | -10.87%0.41 | 13.79%0.33 | 0.00%0.46 | 16.00%0.29 | 15.00%0.46 | |||||
Diluted earnings per share | -10.87%0.41 | 13.79%0.33 | 0.00%0.46 | 16.00%0.29 | 15.00%0.46 | |||||
Currency Unit | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY |
Accounting Standards | IAS | CAS (2007) | IAS | CAS (2007) | IAS | CAS (2007) | IAS | CAS (2007) | IAS | CAS (2007) |
Audit Opinions | Unqualified Opinion | -- | -- | -- | Unqualified Opinion | -- | -- | -- | Unqualified Opinion | -- |
Auditor | Ernst & Young Huaming (Special General Partnership), Ernst & Young | -- | -- | -- | PricewaterhouseCoopers Zhongtian Certified Public Accountants (Special General Partnership) | -- | -- | -- | PricewaterhouseCoopers Zhongtian Certified Public Accountants (Special General Partnership) | -- |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.